Model ATG-016 -Eltanexor - SINE Compound
As a next-generation SINE compound that has shown initial signs of a broader therapeutic window,ATG-016 (eltanexor) could potentially enable higher dosing frequency and an extended period of exposure at higher levels. As a result,ATG-016 (eltanexor) may be used to target a wider range of indications. Given the encouraging efficacy and manageable safety profile demonstrated in the ongoing Phase I/II trial conducted by Karyopharm,we plan to conduct a Phase I/II clinical study for MDS as a fast-to-market strategy in China. Since there is no effective treatment option after hypomethylating agents,there are significant unmet medical needs for MDS patients.
We plan to further develop ATG-016 (eltanexor) for more prevalent indications in the APAC region such as KRAS-mutant solid tumors and virus infection related malignancies such as nasopharyngeal carcinoma.
We are in partnership with Karyopharm Therapeutics for clinical development, manufacturing and commercialization of eltanexor in Greater China (mainland China,Hong Kong,Taiwan,Macau),Australia,New Zealand,South Korea,and the ASEAN countries. We expect to initiate Phase 1/2 clinical trials in both hematological malignancies and solid tumors in 2021.